Crixivan
Product Images NDC 21695-366

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Crixivan (NDC 21695-366). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (01c5574c 1056 49c6 Af20 E950db3f4139 01)

Chemical structure diagram of the active ingredient found in CRIXIVAN. The structure includes multiple benzene rings, nitrogen atoms, hydroxyl groups, and a sulfate component indicated by H2SO4.*

FDA Label Image

Indinavir Protocol Figure 1 (01c5574c 1056 49c6 Af20 E950db3f4139 02)

A line graph depicting the proportion of patients over study weeks 0 to 40 for two treatment groups: Indinavir + Zidovudine + Lamivudine and Zidovudine + Lamivudine. The vertical axis represents the proportion of patients, and the horizontal axis represents study weeks. A data table below the graph shows patient numbers for each group at different time points.*

FDA Label Image

Cd4 Cell Counts Figure 2 (Study ACTG 320)

Line graph showing CD4 cell count change (cells/mm3) over 24 study weeks comparing two treatments: Indinavir + Zidovudine + Lamivudine versus Zidovudine + Lamivudine. The graph includes sample size (N) values at weeks 0, 4, 8, and 24 for both treatment groups.*

FDA Label Image

Indinavir Protocol 028 Figure 3 (01c5574c 1056 49c6 Af20 E950db3f4139 04)

A line graph showing the proportion of patients over 48 weeks in a study for three groups: Indinavir + Zidovudine, Indinavir alone, and Zidovudine alone. The x-axis represents study weeks, and the y-axis represents the proportion of patients, with data points and trend lines for each group. Below the graph, sample sizes for each group at various time points are listed.*

FDA Label Image

Indinavir Protocol 028 Figure 4 (01c5574c 1056 49c6 Af20 E950db3f4139 05)

A line graph showing CD4 cell count change (cells/mm3) over 24 weeks of study. It compares three groups: Indinavir + Zidovudine, Indinavir alone, and Zidovudine alone. The graph plots weekly data points from 0 to 24 weeks, indicating different trends in CD4 cell count changes for each treatment group, with a sample size listed below for each group at the start and end of the study periods.*

FDA Label Image

Indinavir Protocol 035 Figure 5 (01c5574c 1056 49c6 Af20 E950db3f4139 06)

A line chart showing RNA change (Log10 copies/mL) over 24 study weeks for three treatments: Indinavir + Zidovudine + Lamivudine, Indinavir alone, and Zidovudine + Lamivudine. The graph includes a legend and a table indicating sample sizes at various weeks.*

FDA Label Image

Indinavir Protocol 035 Figure 6 (01c5574c 1056 49c6 Af20 E950db3f4139 07)

A line graph showing the proportion of patients over 24 study weeks for three treatment groups: Indinavir plus Zidovudine plus Lamivudine, Indinavir alone, and Zidovudine plus Lamivudine. The x-axis represents study weeks (0 to 24), and the y-axis represents the proportion of patients (0.0 to 1.0). The combination of Indinavir, Zidovudine, and Lamivudine shows the highest patient proportion over time.*

FDA Label Image

Indinavir Protocol 035 Figure 7 (01c5574c 1056 49c6 Af20 E950db3f4139 08)

A line graph depicting CD4 cell count changes (cells/mm³) over 24 study weeks for three treatment groups: Indinavir + Zidovudine + Lamivudine, Indinavir alone, and Zidovudine + Lamivudine. The x-axis represents study weeks, and the y-axis shows CD4 cell count change. Sample sizes (N) for each group at specific study weeks are presented below the graph.*

FDA Label Image

Crixivan 400mg (01c5574c 1056 49c6 Af20 E950db3f4139 09)

CRIXIVAN 400mg capsules packaging label from Physician Partner, distributed by Rebel Distributors Corp. The label states the capsules each contain 400mg of indinavir. It includes the product ID PC036618, NDC 21695-366-18, a warning about medicines that should not be taken with CRIXIVAN, and storage instructions to keep at controlled room temperature. The package size is 18 capsules and is marked RX Only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.